Read about the latest developments in the world of lung cancer. You'll find articles from the last 24 months.
Lung Cancer in the News
August 2019
August 22, 2019:
Added local Tx extended survival in advanced NSCLC
(MedPage Today)
August 9, 2019:
Osimertinib benefit maintained in new OS findings from FLAURA trial in EGFR+ NSCLC
(Targeted Oncology)
July 2019
July 14, 2019:
Correlation between high-dose radiation and lung cancer survival rate
(Medical News Bulletin)
July 12, 2019:
FDA grants orphan drug designation to Imfinzi for small cell lung cancer
(Healio)
July 10, 2019:
Pembrolizumab lengthens overall survival in patients with advanced lung cancer
(MDLinx)
July 5, 2019:
Pemetrexed, bevacizumab maintenance therapy benefits certain NSCLC subsets
(HemOnc Today)
July 3, 2019:
Imfinzi combo therapy extends survival of advanced SCLC patients, phase 3 trial shows
(Immuno-Oncology News)
June 2019
June 28, 2019:
Pfizer receives U.S. FDA approval for its oncology biosimilar, Zirabev™
(BioSpace)
June 18, 2019:
FDA approves Keytruda for metastatic small cell lung cancer
(Healio)
June 14, 2019:
Tecentriq combo prolongs life of lung cancer patients with liver metastases
(Immuno-Oncology News)
June 7, 2019:
Imfinzi still improving survival rates in advanced NSCLC patients, PACIFIC update shows
(Immuno-Oncology News)
June 1, 2019:
Updated results from KEYNOTE-001 show favorable 5-year OS rate in advanced NSCLC
(Targeted Oncology)
May 2019
May 9, 2019:
Burden of Proof: TMB predics response to combo immunotherapy
(MedPage Today)
April 2019
April 23, 2019:
What if we could stop lung cancer before it starts?
(Boston University)
April 12, 2019:
Early phase 3 trial results of tedopi for advanced NSCLC are positive
(Immuno-Oncology News)
April 11, 2019:
FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS≥1%)
(US Food & Drug Administration)
March 2019
March 18, 2019:
FDA approves atezolizumab for extensive-stage small cell lung cancer
(FDA website)
March 12, 2019:
Treatment advances in NSCLC change therapy recommendation in 2019 NCCN Guidelines
(Targeted Oncology)
March 7, 2019:
Pembrolizumab shows durable survival benefit in advanced non-small cell lung cancer
(Healio)
March 6, 2019:
Garon Sheds Light on Next Steps With EGFR-Targeted Agents in NSCLC
(Targeted Oncology)
February 2019
February 23, 2019:
No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
(Cancer Therapy Advisor)
February 20, 2019:
Pembrolizumab Granted FDA's Priority Review for Advanced SCLC
(Targeted Oncology)
February 20, 2019:
SABR improves survival for early, inoperable lung cancer patients
(Health Imaging)
February 11, 2019:
Study: Lung Cancer Risk Drops Dramatically Within 5 Years of Quitting Smoking
(Study Finds)
February 6, 2019:
Osimertinib shows ‘consistent improvement’ in post-progression endpoints for non-small cell lung cancer
(Healio)
February 4, 2019:
FDA Expands Alimta Label With Keytruda for Front Line Treatment of Non-Small Cell Lung Cancer
(Specialty Pharmacy Times)
January 2019
January 29, 2019:
Lung-MAP Trial expands to include all patients with non-small cell lung cancer
(Healio)
January 25, 2019:
Atezolizumab/Bevacizumab Combo Shows Potential in EGFR-Mutant NSCLC
(Targeted Oncology)
January 18, 2019:
Chemoradiotherapy extends survival in limited stage small cell lung cancer
(Healio)
January 2, 2019:
Patients with stage IV disease now living a median 6.8 years after ALK+ NSCLC diagnosis
(News-Medical)
December 2018
December 10, 2018:
Pembrolizumab confers sustained OS benefit in PD-L1-expressing non-small cell lung cancer
(Healio)
December 6, 2018:
Atezolizumab Combo Approved for Frontline Treatment of Metastatic Non-Small Cell Lung Cancer
(Specialty Pharmacy Times)
December 5, 2018:
Immunotherapy Regimen Granted Priority Review in Small Cell Lung Cancer
(Cure Today)
November 2018
November 26, 2018:
FDA approves larotrectinib for solid tumors with NTRK gene fusions
(US Food & Drug Administration)
November 8, 2018:
Exercise Reduces Fatigue, Physical Well-Being Among Patients With Advanced Lung Cancer
(Cure Today)
November 6, 2018:
Immunotherapy provides long-awaited progress in small cell lung cancer
(Cure)
November 4, 2018:
FDA Grants Accelerated Approval to Loratinib for ALK + NSCLC
(Pharmacy Times)
October 2018
October 30, 2018:
FDA Approves Keytruda Combination for Non-Small Cell Lung Cancer Subset
(Cure Today)
October 29, 2018:
Durvalumab Extends Survival vs Placebo in Stage 3 Non-Small Cell Lung CA
(MPR)
October 24, 2018:
SBRT found to be safe treatment for patients with multiple metastases
(News Medical Life Sciences)
October 24, 2018:
Immunotherapy Is Safe for Patients With Cancer Living With HIV
(AJMC)
October 23, 2018:
Immunotherapy Research Key to Moving SCLC Field Forward
(OncLive)
October 22, 2018:
Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
(Cancer Therapy Advisor)
October 19, 2018:
Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
(Cancer Therapy Advisor)
October 19, 2018:
Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers
(Cancer Therapy Advisor)
October 17, 2018:
Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
(Oncology Nurse Advisor)
October 17, 2018:
Entinostat-Keytruda Combo Shows Promise in Certain NSCLC Patients who Received Prior Immune Checkpoint Therapies
(Immuno-Oncology News)
October 16, 2018:
Survival Time Compared for Brigatinib vs Crizotinib in NSCLC
(MPR)
September 2018
September 28, 2018:
Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC
(News Medical Life Sciences)
September 28, 2018:
Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC
(News Medical Life Sciences)
September 27, 2018:
Non-small cell lung cancer patients survive longer when treated with durvalumab
(News Medical Life Sciences)
September 26, 2018:
Brigatinib Superior to Standard of Care Crizotinib in ALK+ NSCLC
(Targeted Oncology)
September 25, 2018:
First-line atezolizumab plus chemotherapy improves PFS for lung cancer
(Healio)
September 12, 2018:
FDA grants priority review to Keytruda for PD-L1-positive NSCLC
(Healio)
September 6, 2018:
FDA extends review of Roche’s Tecentriq by three months
(Pharma Live)
September 5, 2018:
Continuation of Bevacizumab After Progression May Not Improve Survival Outcomes in NSCLC
(Cancer Therapy Advisor)
August 2018
August 21, 2018:
FDA OKs Expanded Keytruda Indication for Non-Small Cell Lung Cancer
(Specialty Pharmacy Times)
August 20, 2018:
FDA Approves Nivolumab for Small Cell Lung Cancer
(Rare Disease Report)
July 2018
July 31, 2018:
High-Resolution Nano-optic Endoscope for Better Disease Detection
(AZO Nano)
July 26, 2018:
Takeda’s Alunbrig improves PFS in phase 3 lung cancer trial
(Pharmaceutical Business Review)
July 23, 2018:
The International Association for the Study of Lung Cancer Publishes Liquid Biopsy Recommendations
(Cancer Therapy Advisor)
July 17, 2018:
PARP Inhibitors May Bring New Hope to Patients with Small Cell Lung Cancer
(Cure Today)
July 17, 2018:
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NS
(Journal for ImmunoTherapy of Cancer)
July 9, 2018:
The ‘Right Track’ to Navigate the Cancer Experience
(Cure Today)
July 2, 2018:
FDA Grants Priority Review to Keytruda Plus Chemotherapy for Lung Cancer Subtype
(Healio)
June 2018
June 28, 2018:
Atezolizumab Plus Chemotherapy Improves Survival in Lung Cancer Subtype
(Healio)
June 28, 2018:
$20 M secured for federally-funded lung cancer research
(Lung Cancer Alliance)
June 26, 2018:
Roche’s Tecentriq threatens BMS’ Optivo in Small-Cell Lung Cancer Market
(Drug Development-Technology)
June 15, 2018:
Keytruda-Chemo Combo Shows Superior Anti-cancer Response in Metastatic NSCLC Phase 3 Trial
(Immuno-Oncology News)
June 12, 2018:
Improved OS with Dacomitnib vs Gefitinib in Selected EGFR + NSCLC
(Cancer Network)
June 12, 2018:
Nivolumab Plus Chemotherapy Prolongs PFS in Lung Cancer With Low Tumor Mutational Burden
(Healio)
June 5, 2018:
Imfinzi Improves Survival of Patients with Advanced Non-Small Cell Lung Cancer, Phase 3 Trial Shows
(Immuno-Oncology News)
June 4, 2018:
KEYNOTE-042: Pembrolizumab Improved Overall Survival in Non-Small Cell Lung Cancer
(Cancer Therapy Advisor)
May 2018
May 31, 2018:
FDA Grants Breakthrough Designation to Crizotinib for Lung Cancer, Lymphoma Subtypes
(Oncology Nursing News)
May 29, 2018:
AstraZeneca’s Late-Stage Study Win Reinforces Its Hold on Particular Segment of Lung Cancer Market
(Seeking Alpha)
May 23, 2018:
Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC
(Cancer Therapy Advisor)
May 17, 2018:
Roche’s Alecensa Beats Pfizer’s Xalkori in Late-Stage Lung Cancer Study
(Seeking Alpha)
May 15, 2018:
PD-1 Inhibitors Safe, Effective in Patients with HIV and Non-Small Cell Lung Cancer
(Infectious Disease Advisor)
May 8, 2018:
FDA Grants Priority Review to Genetech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People with a Sp
(Business Wire)
May 8, 2018:
Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer
(Cancer Therapy Advisor)
May 2, 2018:
FDA Grants Dacomitinib a Priority Review for Lung Cancer Treatment
(Cure)
April 2018
April 19, 2018:
FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC with Most Common EFGR Mutations
(American Society of Clinical Oncology)
April 13, 2018:
Keytruda Beats Chemo at Increasing NSCLC Patients’ Survival, Phase 3 Trial Shows
(Immuno-Oncology News)
April 13, 2018:
Improved QOL with First-Line Osimertinib Compared with Standard of Care in EGFR+ NSCLC
(Targeted Oncology)
April 13, 2018:
Upfront Atezolizumab Combination Pushes Ahead as Promising New Regimen in NSCLC
(Targeted Oncology)
April 9, 2018:
Frontline Pembrolizumab Improves Suvival at Lower PD-L1 Threshold
(OncLive)
April 5, 2018:
Durable Responses, Longer Survival Seen in NSCLC with Nivolumab at 5 Years
(Cancer Network)
March 2018
March 26, 2018:
Atezolizumab Combination Improves OS for Non-Small Cell Lung Cancer
(Healio)
March 20, 2018:
Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
(Lung Cancer Advisor)
March 16, 2018:
U.S. to Cover Advanced Genomic Testing for Medicare Cancer Patients
(Reuters)
March 6, 2018:
Next-Gen Sequencing Predicts NSCLC Tx Response
(MedPage Today)
March 6, 2018:
FDA Approves New Dosing for Bristol-Myers Squibb’s Opdivo
(Reuters)
February 2018
February 16, 2018:
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing
(US Food & Drug Administration)
February 12, 2018:
FDA Grants Priority Review to Lorlatinib for ALK+ NSCLC
(OncLive)
February 8, 2018:
Lung Cancer Screening: Updated Guidelines from CHEST
(Pulmonary Advisor)
January 2018
January 25, 2018:
Durvalumab Takes a Giant Leap into Stage III NSCLC
(ASCO Post)
January 16, 2018:
Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial
(OncLive)
January 16, 2018:
Bunn Expands on Significance of Atezolizumab/Bevacizuab Regimen in NSCLC
(OncLive)
January 14, 2018:
FDA Expands Afatinib’s Approval for Lung Cancer
(OncLive)
December 2017
December 29, 2017:
Intraoperative Molecular Imaging Helps Identify More Cancerous Lung Nodules
(Healio)
December 24, 2017:
Four-Drug Combination Improves NSCLC Outcomes
(Cure Today)
December 18, 2017:
Frontline Tagrisso Granted Priority Review for Lung Cancer Treatment
(Cure Today)
December 14, 2017:
Aggressive Surgery Increases Lung Cancer Patients’ Long-Term Survival, Study Shows
(Lung Disease News)
December 13, 2017:
Early Integrated Palliative Care Improves Coping Strategies for Patients with Incurable Cancer
(Healio)
December 13, 2017:
Even Smokers May Benefit from Targeted Lung Cancer Treatments
(Medical Xpress)
December 6, 2017:
Frontline Atezolizumab Regimen Improves PFS in NSCLC
(OncLive)
December 5, 2017:
Therapies for Stage II to IIIA EGFR-Mutant NSCLC
(ASCO Post)
November 2017
November 30, 2017:
’Aggressive’ Surgery for Early Stage Lung Cancer Provides Better Outcomes
(News Medical)
November 30, 2017:
FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomark
(US Food & Drug Administration)
November 22, 2017:
Adjuvant Gefitinib Improves Disease-Free Survival Among Patients with NSCLC
(Cancer Therapy Advisor)
November 22, 2017:
Ahead of NSCLC Approval Decision, FDA Now Weighing Durvalumab Data in NEJM
(Targeted Oncology)
November 21, 2017:
Patient-Reported Outcomes with Immunotherapy vs Chemotherapy in Advanced NSCLC
(ASCO Post)
November 20, 2017:
Atezolizumab Plus Bevacizumab and Chemotherapy Extends PFS in Non-Small Cell Lung Cancer
(Healio)
November 10, 2017:
Dacomitinib vs. Gefitinib in Advanced NSCLC: Improving Upon Established First-Line Targeted Therapy
(ASCO Post)
November 6, 2017:
Frontline Alecensa Approved for Lung Cancer Treatment
(Cure Today)
October 2017
October 25, 2017:
Pembrolizumab Doubles Median OS For Metastatic Non-Small Cell Lung Cancer
(Healio)
October 17, 2017:
Durvalumab Does Not Worsen Quality of Life Among Patients with Unresectable NSCLC
(Cancer Therapy Advisor)
October 16, 2017:
Nivolumab Provides Better Long-Term Efficacy Compared with Docetaxel in NSCLC
(Oncology Nurse Advisor)
October 13, 2017:
Addition of EGFR Tyrosine Kinase Inhibitor to Chemotherapy in Resistant Non-Small Cell Lung Cancer
(ASCO Post)
October 10, 2017:
Dacomitinib Tops Gefitinib in First-Line EGFR-Mutant NSCLC
(Cancer Network)
October 3, 2017:
Standard Biopsies Retain Significant Role in Lung Cancer Care
(OncLive)
October 3, 2017:
EGFR-Positive NSCLC: Gefitinib-Resistant Patients Should Not Receive Chemotherapy Plus Gefitinib
(Cancer Therapy Advisor)
